Suresh Kamath , MD

Medical Degree: Bangalore Medical College Bengaluru, IMD, 1988

Residency: Royal College of Physicians London, ENG, 1993 (Medicine)

Residency: Brown University Providence, RI, 1995 (Internal Medicine)

Fellowship: University of Cincinnati Cincinnati, OH, 1997 (Nephrology)

American Board of Internal Medicine (Certification Date: 08-21-1996 ) - (Recertification Date: to 11-20-2018 )

American Board of Internal Medicine (Nephrology) (Certification Date: 11-03-1999 ) - (Recertification Date: to 09-01-2019 )

Nephrology

Internal Medicine

Nephrology

Clinical Nephrology, Student, Resident and Fellow Education

2002 -To Present Associate Professor of Medicine, Division of Nephrology and Hypertension, Department of Medicine, University of Cincinnati Medical Center,

- Medical Director, Sub-Specialty Clinic, University Hospital Nephrology and Hypertension, Cincinnati, OH

- Medical Director, Renal Medicine Service, University Hospital, Cincinnati, OH

- Medical Director, Hemodialysis Unit, DCI West Chester, West Chester, OH

- Medical Director, Dialysis Corporaton of America, Tennessee Avenue, Cincinnati, OH

- Attending Nephrologist, The University Hospital, Cincinnati, OH

- Attending Nephrologist, VA Medical Center, Cincinnati, OH

- Attending Nephrologist, Drake Center, Cincinnati, OH

- Attending Nephrologist, West Chester Medical Center, West Chester, OH

- Attending Nephrologist, The Jewish Hospital, Kenwood, OH

10-1997 -03-2002 Medical Director / Lead Physician, Rainelle Medical Center, Rainelle, West Virginia

10-1997 -03-2002 Adjunct Clinical Assistant Professor of Medicine, West Virginia University , Morgan Town, WV

10-1997 -03-2002 Regional Director , Rural Health Education Partnership Program (RHEP) Consortium,

Investigators:Kamath S 2009 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis Role:PI

Investigators:Kamath S 2008 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters

Investigators:Kamath S 2010 A 28-week extension to a 24-week multi-center, randomized, double-blind, active-controlled clinical trial to evaluate the safety and tolerability in vildagliptin 50 mg qd versus sitagliptin 25 mg qd in patients with type 2 diabetes and severe renal insufficiency Role:Sub-Investigator

Investigators:Kamath S 2010 A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients with Chronic Kidney Disease Who are on Hemodialysis Role:Sub-Investigator

Investigators:Kamath S 2010 An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double blind fermagate comparison in hemodialysis patients with hyperphosphatemia Role:Sub-Investigator

Investigators:Kamath S 2009 A Phase 2, randomized, Open-Label, Single-Dose Study of Oral and Intravenous CTAP101 Evaluating Pharmacokinetics, Pharmacodynamics, and Safety in Subjects with Stage 3 and 4 Chronic Kidney Disease, with Vitamin D Insufficiency and Secondary Hyperparathyroidism Role:Sub-Investigator

Investigators:Kamath S 2008 -2009 A Randomized, Single-Blind, Placebo-Controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral doses of FG-4592 in Subjects with Chronic Kidney Disease not Requiring Dialysis Role:Sub-Investigator

Investigators:Kamath S 2008 -2009 A Single-Dose, Open-Label, Dose Determination, Randomized, Cross-Over, Pharmacokinetic Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects with Stage 5 Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis Role:Sub-Investigator

Investigators:Kamath S 2008 -To Present A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects with Stage 3 Chronic Kidney Disease Role:Sub-Investigator

Investigators:Kamath S 2008 -2009 A Mutli-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients Role:Sub-Investigator

Investigators:Kamath S 2008 -2009 A Dose-Ranging Study of Dialysate Containing Soluble Ferric Pryophosphate (SFP) Versus Control in Subjects with ESRD Receiving Chronic Hemodialysis Role:Sub-Investigator

Investigators:Kamath S 2008 -To Present A Multi-Center, Randomized, Double-Blind, Active-Controlled, Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment with Vildagliptin (50mg qd) versus Sitaliptin (25 mg qd) in Patients with Type 2 diabetes and Severe Renal Insufficiency Role:Sub-Investigator

Investigators:Kamath S 2008 -To Present A Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin versus Glipizide in Patients with Type 2 Diabetes Mellitius and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control Role:Sub-Investigator

Investigators:Kamath S 2008 -2009 A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin Alfa Role:Sub-Investigator

Investigators:Kamath S 2008 -2009 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy Role:Sub-Investigator

Investigators:Kamath S 2004 -2005 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of Zemplar Capsule in Reducing Serium Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis Role:Sub-Investigator

Investigators:Kamath S 2004 -2005 A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis Role:Sub-Investigator

Peer Reviewed Publications

Kamath S, Dean D, Peddi V, Schroeder J, Alexander W, Cavallo T, First M (1997. ) Efficacy of OKT3 as primary therapy for histological confirmed acute allograft rejection .Transplantation, , 64 (10 ) ,1428-1432

Kamath S, Dean D, Peddi V, Schroeder J, Alexander W, Cavallo T, First M (1998. ) Primary therapy with OKT3 for Biopsy Proven Acute Renal Allograft Rejection .Transplant Proceedings , , 30 ,1178-1180

Dean D, Kamath S, Peddi V, Schroeder T, First M, Cavallo T (1999. ) A blinded retrospective analysis of renal allograft pathology using the Banff Schema .Transplantation, , 68 (5 ) ,642-645

Peddi V, Kamath S, Schroeder T, Munda R, First M (1998. ) Efficacy of OKT3 as primary therapy for histological confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients .Transplant Proceedings , , 30 ,285-287

Peddi V, Kamath S, Munda R, Demmy A, Alexander J, First M (1998. ) Use of Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation .Clinical Transplantation, , 12 ,401-405

Tumlin, James A; Roy-Chaudhury, Prabir; Koplan, Bruce A; Costea, Alexandru I; Kher, Vijay; Williamson, Don; Pokhariyal, Saurabh; Charytan, David M (2019. ) Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study.BMC nephrology, , 20 (1 ) ,80 More Information

Roy-Chaudhury, Prabir; Tumlin, Jim A; Koplan, Bruce A; Costea, Alexandru I; Kher, Vijay; Williamson, Don; Pokhariyal, Saurabh; Charytan, David M (2018. ) Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle.Kidney international, , 93 (4 ) ,941-951 More Information

Dean, D E; Kamath, S; Peddi, V R; Schroeder, T J; First, M R; Cavallo, T (1999. ) A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management.Transplantation, , 68 (5 ) ,642-5 More Information

Peddi, V R; Kamath, S; Munda, R; Demmy, A M; Alexander, J W; First, M R (1998. ) Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Clinical transplantation, , 12 (5 ) ,401-5

Kamath, S; Dean, D; Peddi, V R; Schroeder, T J; Alexander, J W; Cavallo, T; First, M R (1998. ) Primary therapy with OKT3 for biopsy-proven acute renal allograft rejection.Transplantation proceedings, , 30 (4 ) ,1178-80 More Information

Peddi, V R; Kamath, S; Schroeder, T J; Munda, R; First, M R (1998. ) Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients.Transplantation proceedings, , 30 (2 ) ,285-7 More Information

Kamath, S; Dean, D; Peddi, V R; Schroeder, T J; Alexander, J W; Cavallo, T; First, M R (1997. ) Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.Transplantation, , 64 (10 ) ,1428-32 More Information

renal, kidney

Member American Society of Nephrology

Member American College of Physicians

Member Royal College of Physicians London, England

Academic - Medical Sciences Building
Room G1647
Cincinnati  Ohio, 45267
Phone: 513-558-5471
Fax: 513-558-4309
suresh.kamath@uc.edu